West Pharmaceutical Services/$WST
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About West Pharmaceutical Services
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
- Ticker
- $WST
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 10,800
- Headquarters
- Exton, United States
- Website
- www.westpharma.com
WST Metrics
BasicAdvanced
$28B
50.22
$7.81
1.14
$0.88
0.22%
Price and volume
Market cap
$28B
Beta
1.14
52-week high
$397.16
52-week low
$223.83
Average daily volume
589K
Dividend rate
$0.88
Financial strength
Current ratio
2.822
Quick ratio
1.819
Long term debt to equity
0.097
Total debt to equity
0.104
Dividend payout ratio (TTM)
11.05%
Interest coverage (TTM)
147.88%
Profitability
EBITDA (TTM)
920.8
Gross margin (TTM)
36.79%
Net profit margin (TTM)
16.98%
Operating margin (TTM)
21.97%
Effective tax rate (TTM)
20.34%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
11.51%
Return on equity (TTM)
19.09%
Valuation
Price to earnings (TTM)
50.215
Price to revenue (TTM)
8.469
Price to book
9.23
Price to tangible book (TTM)
9.6
Price to free cash flow (TTM)
64.491
Free cash flow yield (TTM)
1.55%
Free cash flow per share (TTM)
6.081
Dividend yield (TTM)
0.22%
Forward dividend yield
0.22%
Growth
Revenue change (TTM)
12.38%
Earnings per share change (TTM)
16.82%
3-year revenue growth (CAGR)
5.10%
10-year revenue growth (CAGR)
8.63%
3-year earnings per share growth (CAGR)
4.38%
10-year earnings per share growth (CAGR)
18.99%
3-year dividend per share growth (CAGR)
5.07%
10-year dividend per share growth (CAGR)
6.35%
What the Analysts think about WST
Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.
Analyst projections of the future price of West Pharmaceutical Services stock.
Bulls say / Bears say
Second-quarter organic sales rose 12.7% and adjusted EPS rose 28.8%, prompting West to raise its 2026 organic sales growth outlook to 10–11% and adjusted EPS outlook to $8.85–$9.05. (West Pharmaceutical Services)
High-value components are gaining from demand for biologics and GLP-1 drugs, while generic GLP-1 medicines in Asia offer another potential source of growth. (West Pharmaceutical Services, Reuters)
A richer product mix is improving profitability: adjusted operating margin increased to 22.6% in the second quarter from 20.3% a year earlier, as high-value products grew strongly. (West Pharmaceutical Services)
The May cyber incident disrupted production and cost West Vantage about $7 million of second-quarter revenue; the segment's organic sales growth was just 0.8%. (U.S. Securities and Exchange Commission)
West expects third-quarter organic sales growth of 7.0–8.9%, below the second quarter's 12.7%, pointing to a meaningful near-term cooling in growth; the SmartDose sale also weighs on reported comparisons. (West Pharmaceutical Services)
A shift towards oral obesity medicines could weaken demand for injectable delivery systems, a risk for West given its exposure to components used in injectable drugs. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
WST Financial Performance
Revenues and expenses
WST Earnings Performance
Company profitability
Upcoming events
WST News
AllArticlesVideos
Funds containing WST
AllEURUSDGBP
Fund name | Fund size | $WST weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.42% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.40% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.40% |
SPDR MSCI World Health Care$WHEA | $708M | 0.32% |
SPDR MSCI World Health Care£HEAW | $708M | 0.32% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.